Ubs Asset Management Americas Inc Cue Biopharma, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding CUE
# of Institutions
52Shares Held
14MCall Options Held
14.4KPut Options Held
2.6K-
Bleichroeder LP New York, NY5MShares$6.4 Million1.28% of portfolio
-
Slate Path Capital LP New York, NY2.4MShares$3.08 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.03MShares$2.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$968,6220.0% of portfolio
-
Geode Capital Management, LLC Boston, MA509KShares$651,2980.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $45.3M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...